These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28750484)

  • 1. Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy.
    Lee HL; Bae SH; Jang B; Hwang S; Yang H; Nam HC; Sung PS; Lee SW; Jang JW; Choi JY; Han NI; Song BJ; Lee JW; Yoon SK
    Gut Liver; 2017 Nov; 11(6):870-877. PubMed ID: 28750484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy.
    Chen MH; Chen MH; Tsai CY; Chou CT; Lin HY; Huang DF; Huang YH
    Lupus; 2015 Sep; 24(10):1029-36. PubMed ID: 25691509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization.
    Sung PS; Bae SH; Jang JW; Song DS; Kim HY; Yoo SH; Park CH; Kwon JH; Song MJ; You CR; Choi JY; Yoon SK
    Korean J Hepatol; 2011 Dec; 17(4):299-306. PubMed ID: 22310794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
    Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
    J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations.
    Piaserico S; Messina F; Russo FP
    Am J Clin Dermatol; 2019 Dec; 20(6):829-845. PubMed ID: 31222626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.
    Yazici O; Sendur MA; Aksoy S
    World J Gastroenterol; 2014 Jun; 20(22):6716-24. PubMed ID: 24944464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of psoriasis patients with hepatitis B or hepatitis C virus infection.
    Bonifati C; Lora V; Graceffa D; Nosotti L
    World J Gastroenterol; 2016 Jul; 22(28):6444-55. PubMed ID: 27605880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature.
    Snast I; Atzmony L; Braun M; Hodak E; Pavlovsky L
    J Am Acad Dermatol; 2017 Jul; 77(1):88-97.e5. PubMed ID: 28495497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents.
    Juan J; Feld JJ
    Curr Opin Rheumatol; 2014 Jul; 26(4):395-403. PubMed ID: 24841230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.
    Fontaine H; Alric L; Labreuche J; Legendre B; Louvet A; Antoine C; Legendre CM; Hazzan M; Kamar N; Dharancy S; Pol S; Duhamel A; Mathurin P
    J Hepatol; 2019 May; 70(5):831-838. PubMed ID: 30879789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients.
    Markovic S; Drozina G; Vovk M; Fidler-Jenko M
    Hepatogastroenterology; 1999; 46(29):2925-30. PubMed ID: 10576374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
    Ogawa E; Furusyo N; Murata M; Toyoda K; Hayashi T; Ura K
    Liver Int; 2018 Jan; 38(1):76-83. PubMed ID: 28618152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.
    Loras C; Gisbert JP; Mínguez M; Merino O; Bujanda L; Saro C; Domenech E; Barrio J; Andreu M; Ordás I; Vida L; Bastida G; González-Huix F; Piqueras M; Ginard D; Calvet X; Gutiérrez A; Abad A; Torres M; Panés J; Chaparro M; Pascual I; Rodriguez-Carballeira M; Fernández-Bañares F; Viver JM; Esteve M; ;
    Gut; 2010 Oct; 59(10):1340-6. PubMed ID: 20577000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GB virus C (GBV-C) infection in patients with chronic hepatitis C. Influence on liver disease and on hepatitis virus behaviour: effect of interferon alfa therapy.
    Pawlotsky JM; Roudot-Thoraval F; Muerhoff AS; Pellerin M; Germanidis G; Desai SM; Bastie A; Darthuy F; Rémiré J; Zafrani ES; Soussy CJ; Mushahwar IK; Dhumeaux D
    J Med Virol; 1998 Jan; 54(1):26-37. PubMed ID: 9443106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
    Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
    World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients.
    Mahale P; Kontoyiannis DP; Chemaly RF; Jiang Y; Hwang JP; Davila M; Torres HA
    J Hepatol; 2012 Dec; 57(6):1177-85. PubMed ID: 22871500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
    Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
    J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study.
    Chiu HY; Hui RC; Huang YH; Huang RY; Chen KL; Tsai YC; Lai PJ; Wang TS; Tsai TF
    Acta Derm Venereol; 2018 Oct; 98(9):829-834. PubMed ID: 29972221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of HCV-RNA after ultracentrifugation of serum samples during the follow-up of chronic hepatitis C patients with a sustained virological response may predict reactivation of hepatitis C virus infection.
    Castillo I; Bartolomé J; Quiroga JA; Barril G; Carreño V
    Aliment Pharmacol Ther; 2009 Sep; 30(5):477-86. PubMed ID: 19523175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.